Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Similac Advance

This article was originally published in The Tan Sheet

Executive Summary

Ross Products' infant formula fortified with Martek Biosciences' DHA, ARA fatty acid oils will be available by mid-April in food, drug, mass stores, Abbott Labs division says. Advance will come in 12.9 oz. and 25.7 oz. powder, 32 oz. ready-to-feed plastic bottle; formula will be priced at 15% premium over existing products. Ross says it has received FDA clearance for its GRAS petition, submitted Jan. 2; firm will be second to market fortified formula in the U.S. following Mead Johnson's launch of Enfamil LIPIL, reaching shelves this month (1"The Tan Sheet" Jan. 14, 2002, p. 3)...
Advertisement

Related Content

Nestle, Martek sign deal
Enfamil LIPIL Future “Unique Blend” Claims Should Be Clarified, NAD Says
Similac Advance
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Topics

Advertisement
UsernamePublicRestriction

Register

PS093674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel